Nebojsa Janjic has been the Chief Science Officer at SomaLogic since January 2009. Prior to joining SomaLogic, Dr. Janjic was a founder and CSO of Replidyne, Inc., a biotechnology company focusing on the development of novel small-molecule antibacterial agents. The mission of Replidyne continues on through a successor company, Crestone, Inc., where he currently serves as advisor and Chairman of the Board. Prior to Replidyne, he was among the initial group of scientists to join the original aptamer company, NeXagen, which became NeXstar Pharmacauticas. As Senior Director of Drug Discovery at NeXstar, he was responsible for creating a pipeline of aptamer-based drug candidates for pre-clinical and clinical development. His contributions included the discovery and early development of Macugen, the first-in-class, FDA-approved treatment for macular degeneration targeting VEGF, and named Innovative Pharmaceutical Product of the Year in 2005.
Dr. Janjic received his bachelor’s degree in molecular biology and doctorate in physical organic chemistry from the University of Washington in Seattle. He completed his postdoctoral training at the Scripps Research Institute in La Jolla as a Cancer Research Institute Fellow.
